Twist Bioscience Corp

CRISPR Therapeutics

Recursion Pharmaceuticals

CareDx

Adaptive Biotechnologies

Veracyte

Ionis Pharma

Nurix Therapeutics, Inc

Intellia Therapeutics

10X Genomics

ARK Genomic Revolution Multi-Sector ETF

ARKG is an actively managed fund that targets companies involved in the genomics industry.

VanEck Vectors Biotech ETF

ProShares Ultra Nasdaq Biotechnology

First Trust NYSE Arca Biotechnology Index Fund

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

iShares Nasdaq Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

iShares Neuroscience And Healthcare ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

SPDR S&P Biotech ETF

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma associated with mental health are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.

Why Now Could Be The Time To Consider Neuroscience Investments

The rapid cost declines associated with gene editing and gene synthesis are turbo-charging scientific creativity, enabling the testing of hypotheses that, until now, have been cost-prohibitive, ARK Invest wrote in a recent newsletter.

Opportunities Emerge From Rapid Cost Declines in Gene Editing and Synthesis

Biotech stocks got crushed in the first half of the year as a risk-off sentiment emerged and the growthiest segments of the market were punished, but have rebounded in recent months, with some companies posting highly impressive gains.

ARKG Holding Butterfly Network Increases 127% in Past Month

Beam Therapeutics

Editas Medicine

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

A Comprehensive Guide to Genomic ETFs

CVS Health Corp (CVS) is seeking to buy Signify Health Inc. (SGFY) as it looks to expand in-home health services, the Wall Street Journal reported on Sunday, citing sources. Signify Health is exploring strategic alternatives including a sale, the Wall Street Journal reported this past week.

ARKG Top Holding Signify Reported to Be Acquisition Target by CVS

ARK Innovation ETF

Investors reinstated their positions in the growthiest segments of the market in July. After U.S. equities posted their worst first-half performance since 1970 as inflation concerns, Fed rate hikes, and slowing economic growth weighed on markets, U.S. equities pulled off a stellar comeback in July.

Investors Flocked to ARKK and ARKG in July as Growth Rebounded

The biotech sector can offer unique opportunities and strong returns to investors willing to stomach the volatility heightened by the current economic environment.

Shares of Verve Therapeutics Up 84% in Past Month; Get Exposure With ARKG

The ARK Genomic Revolution ETF (ARKG) has rebounded in the past five weeks, partially offsetting negative performance and outflows experienced since the rotation to cyclicals began in February 2021. A top performer in the health and biotech equities ETF category, ARKG has returned 30.

Everything Advisors Need to Know About ARKG's Q2 Performance

Biotech's rally hasn't let up, as shares of the ARK Genomic Revolution ETF (ARKG) have increased nearly 37% over the past month.  A surge in biotech share prices that began in mid-June is lasting longer than skeptics expected.

ARKG Increases Over 36% as Biotech's Rebound Enters Second Month

Active management may have unique advantages in the current market environment, characterized by higher volatility and wide disparity among sectoral performance. The comeback of smaller-caps and equal weight might have positive implications for active managers, as their portfolios are often closer to equal- than cap-weighted, according to Anu Ganti, senior director, index investment strategy, S&P [.

Small-Caps' Comeback Advantageous for Active Managers

The ARK Genomic Revolution ETF (ARKG) has increased over 5.5% by mid-day Thursday as biotech continues to rally and broader markets increase.  The fund is up 18.08% over the past five days and 13.7% over the past month, partially recouping losses from earlier in the year.

ARKG Holding Accolade Up 60% in Past Month

Biotech funds began their rebound last week as positive trial data and merger and acquisition news revived the sector. The ARK Genomic Revolution ETF (ARKG) rallied 7.15% over one week, ahead of all other ETFs in the health and biotech equities ETFs category, according to VettaFi.

ARKG Leads in 1-Week Returns as Biotech Rebounds

ARK Web x.0 ETF

Virtus LifeSci Biotech Clinical Trials ETF

Renaissance IPO ETF

WisdomTree Cloud Computing Fund

The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.

ETFs Winners of S&P 500's Second Best Week in 2022

Ultima Genomics has claimed that its first instrument, the UG100, will sequence a human genome for under $100. The news surprised and perhaps delighted the life sciences community, as the price to sequence a human genome using Illumina (ILMN) technology essentially plateaued once it crossed the $1,000 barrier in 2014, according to ARK Invest.

Get Exposure to the Genomic Revolution With ARKG

With a targeted disruptive innovation biotechnology-related exchange traded fund strategy, investors can focus on companies driving change in targeted therapeutics, bioinformatics, CRISPR technology, and more. In the recent webcast, Change the DNA of Your Portfolio: Growth Opportunities Through Genomics, Nicholas Grous, associate portfolio manager at ARK Invest, highlighted five innovation platforms that will experience long-term [.

An Innovative ETF Opportunity That Taps Into Our Increased Understanding of the Human Genome

Thanks to DNA sequencing and the genomic revolution, we could be on the cusp of a brand-new era of healthcare solutions that could extend and enhance the quality of human life. Several key biotech companies are pioneering scientific developments that can change everything we know about healthcare.

Change the DNA of Your Portfolio: Growth Opportunities Through Genomics

Burning Rock Biotech

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Cathie Wood Is Selling Gene Editing Stocks. Here's Why.

In the healthcare space, it's often said that an ounce of prevention is worth a pound of cure, and that's undeniably true when it comes to cancer prevention and treatment. A clear avenue for bolstering cancer patient outcomes and potentially improving preventative measure is through enhanced genetics-based testing.

Some ARKG Components Could Lead in Genetic Testing

ARKG has made a massive reshuffling of its portfolio in the past one year, but that is yet to generate results. ARKG had a steep price fall over the past one month, and had a poor price performance over the short and medium term.

ARKG: Don't Expect Any Favorable Return In Short Or Medium Term

ARK Fintech Innovation ETF

ARK Space Exploration & Innovation ETF

ARK Israel Innovative Technology ETF

The 3D Printing ETF

Early-stage technology investment returns are likely to be highly positively skewed, underscoring the importance of a small number of contributors in ARK's portfolios. Limiting individual position weights results in an implicit mean reversion strategy, which is more suited to cyclical value type investments.

ARK Invest: Attempting The Improbable

ARK Industrial Innovation ETF

Catherine Wood (Trades, Portfolio) is a growth stock investor who believes disruptive innovation and technology are the keys to great investing returns. Her firm's flagship fund, the Ark Innovation ETF ( ARKK , Financial), focuses on four main pillars:

Ark is Sinking: Can Cathie Wood Bounce Back?

Teladoc

Shares of the telemedicine provider were cut in half on Thursday, pressuring ARKK and other ETFs.

ARK Crushed By Concentrated Bet In Teladoc

Investors should keep an eye on innovative platforms-related exchange traded funds to capture tomorrow's growth ideas today. In the recent webcast, Refining Your Innovation Exposure: How to Access Tomorrow's Opportunities, Brett Winton, Director of Research, ARK Invest; and Thomas Hartmann-Boyce, Client Portfolio Manager, ARK Invest, argue that actively managed strategies are better positioned to quickly [.

Why Investors Should Consider ETFs That Target Innovation Platforms

ARK's research identifies five innovation platforms that are evolving simultaneously, transforming the world around us. These platforms are Artificial Intelligence (AI), Blockchain Technology, Energy Storage, Robotics, and DNA Sequencing.

Refining Your Innovation Exposure: How to Access Tomorrow's Opportunities

Tuttle Capital Short Innovation ETF

The ARK CEO remains steadfast in her belief that her exchange-traded funds will outperform again.

News for ARK Genomic Revolution Multi-Sector ETF ETF (ARKG)